123 related articles for article (PubMed ID: 11713805)
1. Technology evaluation: leukemia therapy, University of Pennsylvania.
Orr RM
Curr Opin Mol Ther; 1999 Jun; 1(3):399-403. PubMed ID: 11713805
[TBL] [Abstract][Full Text] [Related]
2. Oligonucleotide therapeutics: clothing the emperor.
Gewirtz AM
Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
[TBL] [Abstract][Full Text] [Related]
3. Antisense oligodeoxynucleotides for the treatment of chronic myelogenous leukemia: are they still a promise?
de Fabritiis P; Calabretta B
Haematologica; 1995; 80(4):295-9. PubMed ID: 7590496
[No Abstract] [Full Text] [Related]
4. Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study.
Luger SM; O'Brien SG; Ratajczak J; Ratajczak MZ; Mick R; Stadtmauer EA; Nowell PC; Goldman JM; Gewirtz AM
Blood; 2002 Feb; 99(4):1150-8. PubMed ID: 11830460
[TBL] [Abstract][Full Text] [Related]
5. Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules.
Opalinska JB; Kalota A; Gifford LK; Lu P; Jen KY; Pradeepkumar PI; Barman J; Kim TK; Swider CR; Chattopadhyaya J; Gewirtz AM
Nucleic Acids Res; 2004; 32(19):5791-9. PubMed ID: 15514112
[TBL] [Abstract][Full Text] [Related]
6. Technology evaluation: ISIS-3521.
Li K; Zhang J; Sirois P; Hu Y
Curr Opin Mol Ther; 1999 Jun; 1(3):393-8. PubMed ID: 11713804
[TBL] [Abstract][Full Text] [Related]
7. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
[TBL] [Abstract][Full Text] [Related]
8. Multigene targeting with antisense oligodeoxynucleotides: an exploratory study using primary human leukemia cells.
Opalinska JB; Machalinski B; Ratajczak J; Ratajczak MZ; Gewirtz AM
Clin Cancer Res; 2005 Jul; 11(13):4948-54. PubMed ID: 16000594
[TBL] [Abstract][Full Text] [Related]
9. Coding sequence and intron-exon junctions of the c-myb gene are intact in the chronic phase and blast crisis stages of chronic myeloid leukemia patients.
Bussolari R; Candini O; Colomer D; Corradini F; Guerzoni C; Mariani SA; Cattelani S; Silvestri C; Pecorari L; Iacobucci I; Soverini S; Fasano T; Martinelli G; Cervantes F; Calabretta B
Leuk Res; 2007 Feb; 31(2):163-7. PubMed ID: 16797705
[TBL] [Abstract][Full Text] [Related]
10. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
12. A DNA uptake-stimulating protein increases the antiproliferative effect of c-myb antisense oligonucleotide on leukemic cells.
Tóth G; Schlammadinger J; Aradi J; Antal-Szalmás P; Sipka S; Balázs M; Kovács P; Fehér Z; Falus A
Cell Biol Int; 2004; 28(11):817-23. PubMed ID: 15563404
[TBL] [Abstract][Full Text] [Related]
13. The clinical experience of antisense therapy to ICAM-1 in Crohn's disease.
Yacyshyn B; Bowen-Yacyshyn MB; Shanahan W
Curr Opin Mol Ther; 1999 Jun; 1(3):332-5. PubMed ID: 11713798
[TBL] [Abstract][Full Text] [Related]
14. ISIS-3521. Isis Pharmaceuticals.
Li K; Zhang J
Curr Opin Investig Drugs; 2001 Oct; 2(10):1454-61. PubMed ID: 11890365
[TBL] [Abstract][Full Text] [Related]
15. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.
Perrotti D; Cesi V; Trotta R; Guerzoni C; Santilli G; Campbell K; Iervolino A; Condorelli F; Gambacorti-Passerini C; Caligiuri MA; Calabretta B
Nat Genet; 2002 Jan; 30(1):48-58. PubMed ID: 11753385
[TBL] [Abstract][Full Text] [Related]
16. Evidence for higher-order structure formation by the c-myb 18-mer phosphorothioate antisense (codons 2-7) oligodeoxynucleotide: potential relationship to antisense c-myb inhibition.
Vilenchik M; Benimetsky L; Kolbanovsky A; Miller P; Stein CA
Antisense Nucleic Acid Drug Dev; 2001 Apr; 11(2):87-97. PubMed ID: 11334144
[TBL] [Abstract][Full Text] [Related]
17. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
Olsson-Strömberg U; Aleskog A; Björnberg A; Höglund M; Simonsson B; Bengtsson M; Barbany G; Larsson R; Lindhagen E
Anticancer Drugs; 2006 Jul; 17(6):631-9. PubMed ID: 16917208
[TBL] [Abstract][Full Text] [Related]
18. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.
Gyurkocza B; Plescia J; Raskett CM; Garlick DS; Lowry PA; Carter BZ; Andreeff M; Meli M; Colombo G; Altieri DC
J Natl Cancer Inst; 2006 Aug; 98(15):1068-77. PubMed ID: 16882944
[TBL] [Abstract][Full Text] [Related]
19. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
[TBL] [Abstract][Full Text] [Related]
20. Emerging treatments in acute myeloid leukaemia.
Kell J
Expert Opin Emerg Drugs; 2004 May; 9(1):55-71. PubMed ID: 15155136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]